Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters
1 other identifier
observational
129
1 country
1
Brief Summary
The early diagnosis of Alzheimer's disease is essential to enable patients to have access to the available treatments. However, there is a delay between the diagnosis and the onset of symptoms, which can range from 1 year to more than 5 years. In clinical practice, the hippocampal volume, measured by the Scheltens index, is currently used as a marker of the progression of the disease. The purpose of this study is to determine whether the patient's sex, age and ethnicity can influence the delay in the expression of cognitive troubles reported by the family at the first medical consultation, as well as to determine if there is a correlation between the delay reported by the family and the Scheltens index.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2016
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2017
CompletedFirst Submitted
Initial submission to the registry
January 17, 2018
CompletedFirst Posted
Study publicly available on registry
January 23, 2018
CompletedJanuary 23, 2018
January 1, 2018
1.4 years
January 17, 2018
January 17, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Age
Age
Between 01-01-2010 and 31-01-2013
Sex
Sex
Between 01-01-2010 and 31-01-2013
Ethnic origin
Ethnic origin
Between 01-01-2010 and 31-01-2013
Symptoms-diagnose time interval
Interval of time between the apparition of the first symptoms, as reported by the family, and the diagnose.
Between 01-01-2010 and 31-01-2013
Scheltens scale
Evaluation of the hippocampal atrophy by means of magnetic resonance imaging. Scale from 0 (normal) to 4.
Between 01-01-2010 and 31-01-2013
Study Arms (1)
Alzheimer Disease
Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
Interventions
Eligibility Criteria
Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
You may qualify if:
- Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Murielle Surquinlead
Study Sites (1)
CHU Brugmann
Brussels, Belgium
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Florence Benoit, MD
CHU Brugmann
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Head of clinic
Study Record Dates
First Submitted
January 17, 2018
First Posted
January 23, 2018
Study Start
May 1, 2016
Primary Completion
October 1, 2017
Study Completion
October 1, 2017
Last Updated
January 23, 2018
Record last verified: 2018-01
Data Sharing
- IPD Sharing
- Will not share